Pharma Merger
SAN FRANCISCO — Directors are selling Dermira, a biopharmaceutical company, too cheaply through an unfair process to nonparty Eli Lilly, for $18.75 a share or $1.1 billion, a shareholder claims in federal court.
SAN FRANCISCO — Directors are selling Dermira, a biopharmaceutical company, too cheaply through an unfair process to nonparty Eli Lilly, for $18.75 a share or $1.1 billion, a shareholder claims in federal court.